PDCD1 and melanoma: In this context, it is noteworthy that the predominant types of cutaneous malignancies in XP are melanoma, squamous cell carcinoma and basal cell carcinoma, the advanced forms of which are responsive to monoclonal antibody-based, mostly PD-1-targeted, immunotherapy (58–61).